Long-term antibiotic therapy for patients with endocarditis
Suppressive Antibiotic Therapy for Prosthetic Valve or Implantable Device Related Infectious Endocarditis
This study tests whether long-term antibiotic treatment can help patients with endocarditis who have devices like heart valves avoid infections and live longer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Locations | 1 site (Strasbourg) |
| Trial ID | NCT06107309 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients with endocarditis, particularly those with prosthetic or implantable devices, who have undergone suppressive antibiotic therapy. It aims to evaluate the effectiveness of long-course antibiotic treatment in preventing infectious relapse and prolonging survival in patients who are not candidates for invasive procedures. The study will analyze data from patients treated between January 2016 and January 2023, assessing outcomes related to infection control and patient survival. The approach is based on existing guidelines suggesting long-term antibiotic use in similar cases.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who have received suppressive antibiotic therapy for endocarditis.
Not a fit: Patients who have expressed opposition to participating in the study or who have died or lost sight before starting suppressive antibiotic therapy will not benefit.
Why it matters
Potential benefit: If successful, this study could provide a viable long-term treatment option for patients with endocarditis, potentially improving their survival rates.
How similar studies have performed: While the approach of long-term antibiotic therapy has been suggested in guidelines, this specific observational study is novel in its focus on endocarditis patients with prosthetic devices.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: * Major subject (≥18 years old) * Subject having benefited from suppressive antibiotic therapy after collegial decision in CPR Endocarditis during the period from January 1, 2016 to January 31, 2023 * Subject not opposing the reuse of their data for the purposes of this research. Exclusion criteria: * Subject having expressed opposition to participating in the study * Death or loss of sight of the patient before initiation of suppressive antibiotic therapy.
Where this trial is running
Strasbourg
- Service des Maladies Infectieuses et Tropicales - CHU de Strasbourg - France — Strasbourg, France (Recruiting)
Study contacts
- Study coordinator: Yvon RUCH, MD
- Email: yvon.ruch@chru-strasbourg.fr
- Phone: 33 3 69 55 12 19
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.